Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | MDM2 amp TP53 wild-type |
Therapy | BI 907828 |
Indication/Tumor Type | lung squamous cell carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MDM2 amp TP53 wild-type | lung squamous cell carcinoma | sensitive | BI 907828 | Preclinical - Pdx | Actionable | In a preclinical study, BI 907828 induced prolonged tumor stasis and tumor regression in patient-derived xenograft (PDX) models of MDM2-amplified, TP53 wild-type squamous cell lung carcinoma (PMID: 39259562). | 39259562 |
PubMed Id | Reference Title | Details |
---|---|---|
(39259562) | Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2-p53 Antagonist Suitable for Intermittent Dose Schedules. | Full reference... |